Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.52 |
| ▸ | CA12 | O43570 | 2/20 | 0.52 |
| ▸ | CA7 | P43166 | 2/20 | 0.52 |
| ▸ | CA9 | Q16790 | 2/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.52 |
| ▸ | CA2 | P00918 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | TTR | P02766 | 1/20 | 0.46 |
| ▸ | DPP4 | P27487 | 1/20 | 0.46 |
| ▸ | MET | P08581 | 1/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
| ▸ | CA6 | P23280 | 1/20 | 0.46 |
| ▸ | CA5A | P35218 | 1/20 | 0.46 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
| ▸ | PTPRB | P23467 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6987937 | 0.88 | CA12 (0.55) | CA1CA12CA7CA9CA14 | |
| SCHEMBL30944751 | 0.88 | CA12 (0.55) | CA1CA12CA7CA9CA14 | |
| SCHEMBL4495406 | 0.81 | CYP4F2 (0.56) | CA1CA2KMT2AGLANAMPT | |
| SCHEMBL4087559 | 0.81 | CA12 (0.56) | CA1CA12CA7CA9CA14 | |
| SCHEMBL4087563 | 0.81 | CA12 (0.56) | CA1CA12CA7CA9CA14 | |
| SCHEMBL24817817 | 0.81 | CA2 (0.47) | CA1CA2NAMPTMAPTLMNA | |
| SCHEMBL1579754 | 0.80 | CA12 (0.69) | CA1CA12CA7CA9CA14 | |
| SCHEMBL7748042 | 0.80 | CA12 (0.57) | CA1CA12CA7CA9CA14 | |
| SCHEMBL7748046 | 0.80 | CA12 (0.57) | CA1CA12CA7CA9CA14 | |
| SCHEMBL693427 | 0.79 | CA2 (0.53) | CA1CA2KMT2AGLANAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7504403-B2 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2009-03-17 | — | — | US | disclosed |
| EP-1716150-B1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC (US) | 2008-04-23 | — | — | EP | disclosed |
| EP-1716150-A2 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2006-11-02 | — | — | EP | disclosed |
| US-20050187223-A1 | Substituted heterocyclic compounds and methods of use | AMGEN, INC. | 2005-08-25 | — | — | US | disclosed |
| WO-2005070932-A2 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2005-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050187223-A1 | Substituted heterocyclic compounds and methods of use | MYLK2, MUSK, MAPT | CA1 2254/4885CA12 3656/4885CA7 4250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.